Douglas C. Marchion

3.5k total citations
66 papers, 2.3k citations indexed

About

Douglas C. Marchion is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Douglas C. Marchion has authored 66 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Molecular Biology, 18 papers in Oncology and 14 papers in Cancer Research. Recurrent topics in Douglas C. Marchion's work include Histone Deacetylase Inhibitors Research (19 papers), Protein Degradation and Inhibitors (14 papers) and Ovarian cancer diagnosis and treatment (12 papers). Douglas C. Marchion is often cited by papers focused on Histone Deacetylase Inhibitors Research (19 papers), Protein Degradation and Inhibitors (14 papers) and Ovarian cancer diagnosis and treatment (12 papers). Douglas C. Marchion collaborates with scholars based in United States, Australia and France. Douglas C. Marchion's co-authors include Pamela N. Münster, Elona Biçaku, Daniel M. Sullivan, Adil Daud, Morgen Schmitt, Joel G. Turner, Andrea Basso, Neal Rosen, Scott Thomas and Johnathan M. Lancaster and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Douglas C. Marchion

63 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas C. Marchion United States	23	1.8k	609	253	156	155	66	2.3k
Valeria Masciullo Italy	25	1.5k 0.8×	722 1.2×	361 1.4×	214 1.4×	170 1.1×	53	2.5k
James S. Hardwick United States	18	1.7k 1.0×	454 0.7×	200 0.8×	269 1.7×	170 1.1×	25	2.5k
Míriam Molina‐Arcas United Kingdom	27	1.4k 0.8×	1.3k 2.1×	308 1.2×	341 2.2×	330 2.1×	49	2.8k
Heather M. O’Hagan United States	23	1.6k 0.9×	548 0.9×	486 1.9×	187 1.2×	174 1.1×	49	2.2k
Petra Obexer Austria	24	1.2k 0.7×	396 0.7×	325 1.3×	248 1.6×	124 0.8×	43	1.8k
Michele A. Glozak United States	14	2.4k 1.4×	682 1.1×	198 0.8×	257 1.6×	70 0.5×	18	2.9k
Hongling Peng China	24	885 0.5×	404 0.7×	470 1.9×	217 1.4×	205 1.3×	117	1.7k
Zunyan Dai United States	27	2.2k 1.3×	665 1.1×	900 3.6×	130 0.8×	290 1.9×	45	3.0k
Makoto Tsuneoka Japan	27	1.5k 0.9×	342 0.6×	239 0.9×	245 1.6×	129 0.8×	51	2.1k
Lijun Di China	25	1.0k 0.6×	602 1.0×	389 1.5×	236 1.5×	188 1.2×	102	1.9k

Countries citing papers authored by Douglas C. Marchion

Since Specialization

Citations

This map shows the geographic impact of Douglas C. Marchion's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas C. Marchion with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas C. Marchion more than expected).

Fields of papers citing papers by Douglas C. Marchion

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas C. Marchion. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas C. Marchion. The network helps show where Douglas C. Marchion may publish in the future.

Co-authorship network of co-authors of Douglas C. Marchion

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas C. Marchion. A scholar is included among the top collaborators of Douglas C. Marchion based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas C. Marchion. Douglas C. Marchion is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Berglund, Anders, John Puskas, Sean Yoder, et al.. (2025). Evaluating the Radiation Sensitivity Index and 12-Chemokine Gene Expression Signature for Clinical Use in a CLIA Laboratory. Cancer Research Communications. 5(3). 389–397. 2 indexed citations

Tian, Yijun, Paul A. Stewart, Yury O. Núñez López, et al.. (2023). Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer. International Journal of Molecular Sciences. 24(3). 1830–1830. 8 indexed citations

Marchion, Douglas C., Susan McCarthy, Ardeshir Hakam, et al.. (2021). Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes. PLoS ONE. 16(11). e0256615–e0256615. 3 indexed citations

Napoli, Marco, Zheng‐Xiang Li, Marlese A. Pisegna, et al.. (2020). Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation. Nature Communications. 11(1). 15 indexed citations

Cao, Yu, Jimena Trillo-Tinoco, Rosa A. Sierra, et al.. (2019). ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. Nature Communications. 10(1). 1280–1280. 111 indexed citations

Cao, Yu, Jimena Trillo-Tinoco, Rosa A. Sierra, et al.. (2019). Publisher Correction: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. Nature Communications. 10(1). 3680–3680. 5 indexed citations

Xiong, Yin, Douglas C. Marchion, Forough Abbasi, et al.. (2015). Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance. Gynecologic Oncology. 140(2). 259–263. 16 indexed citations

Marchion, Douglas C., Yin Xiong, C. McClung, et al.. (2015). Unique molecular portraits of ovarian cancer: Implications for prognostics and targeted therapeutics. Gynecologic Oncology. 137. 116–116.

Byrne, Frances L., Ivan K. H. Poon, Susan C. Modesitt, et al.. (2014). Metabolic Vulnerabilities in Endometrial Cancer. Cancer Research. 74(20). 5832–5845. 91 indexed citations

10.

Bosquet, Jesús González, et al.. (2014). Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data. Cancer Research. 74(14). 3902–3912. 25 indexed citations

11.

Judson, Patricia L., Douglas C. Marchion, Yin Xiong, et al.. (2012). Characterizing the Efficacy of Fermented Wheat Germ Extract Against Ovarian Cancer and Defining the Genomic Basis of Its Activity. International Journal of Gynecological Cancer. 22(6). 960–967. 18 indexed citations

12.

Daud, Adil, Jana L. Dawson, Ronald C. DeConti, et al.. (2009). Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial. Clinical Cancer Research. 15(7). 2479–2487. 78 indexed citations

13.

Münster, Pamela N., Douglas C. Marchion, Elona Biçaku, et al.. (2009). Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC. Clinical Cancer Research. 15(7). 2488–2496. 119 indexed citations

14.

Biçaku, Elona, Douglas C. Marchion, Morgen Schmitt, & Pamela N. Münster. (2007). The histone deacetylase inhibitor-induced potentiation of tamoxifen involves autophagy.. Molecular Cancer Therapeutics. 6. 1 indexed citations

15.

Gump, Jana, Douglas C. Marchion, Elona Biçaku, et al.. (2006). Valproic acid sensitizes human melanoma cells to karenitecin in vitro and in vivo. Cancer Research. 66. 320–320.

16.

Marchion, Douglas C., Elona Biçaku, Adil Daud, Daniel M. Sullivan, & Pamela N. Münster. (2005). In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Molecular Cancer Therapeutics. 4(12). 1993–2000. 69 indexed citations

17.

Marchion, Douglas C., Elona Biçaku, Adil Daud, et al.. (2004). Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. Journal of Cellular Biochemistry. 92(2). 223–237. 154 indexed citations

18.

Münster, Pamela N., Douglas C. Marchion, Andrea Basso, & Neal Rosen. (2002). Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.. PubMed. 62(11). 3132–7. 130 indexed citations

19.

Cheung, David T., Patricia A. Weber, Albert Grobe, et al.. (2001). A new method for the preservation of aortic valve homografts.. PubMed. 10(6). 728–34; discussion 734. 10 indexed citations

20.

Cheung, David T., Suk Jung Choo, Albert Grobe, et al.. (1999). Behavior of vital and killed autologous pericardium in the descending aorta of sheep. Journal of Thoracic and Cardiovascular Surgery. 118(6). 998–1005. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact